Latest Articles

Publication Date
All News Scientific
Cancer-linked chemical found in top European baby pacifier brands, including some sold in Israel - Ynetnews

Cancer-linked chemical found in top European baby pacifier brands, including some sold in Israel Ynetnews

Published: Oct. 19, 2025, 9:17 p.m.
Read Full Article
Dydrogesterone Drug Market expected to grow from USD 846.3 Million in 2025 to USD 1,500 Million by 2035 - industrytoday.co.uk

Dydrogesterone Drug Market expected to grow from USD 846.3 Million in 2025 to USD 1,500 Million by 2035 industrytoday.co.uk

Published: Oct. 19, 2025, 11:06 a.m.
Read Full Article
Catamenial Pneumothorax Without Thoracic Endometriosis: A Case Report From the Gulf Cooperation Council (GCC) Region - Cureus

Catamenial Pneumothorax Without Thoracic Endometriosis: A Case Report From the Gulf Cooperation Council (GCC) Region Cureus

Published: Oct. 19, 2025, 12:43 a.m.
Read Full Article
Minister ‘sorry’ for endometriosis treatment waits as she launches new framework - westernpeople.ie

Minister ‘sorry’ for endometriosis treatment waits as she launches new framework westernpeople.ie

Published: Oct. 18, 2025, 6:10 p.m.
Read Full Article
Ireland’s first national endometriosis framework launched - Medical Independent

Ireland’s first national endometriosis framework launched Medical Independent

Published: Oct. 18, 2025, 3:26 p.m.
Read Full Article
New endometriosis framework will provide ‘faster clinical pathway’ for sufferers, says Minister for Health - The Irish Independent

New endometriosis framework will provide ‘faster clinical pathway’ for sufferers, says Minister for Health The Irish Independent

Published: Oct. 18, 2025, 3:02 p.m.
Read Full Article
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen - The AI Journal

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen The AI Journal

Published: Oct. 18, 2025, 10:28 a.m.
Read Full Article
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen - Business Wire

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen Business Wire

Published: Oct. 18, 2025, 10 a.m.
Read Full Article
The female scientists who finally found an answer to endometriosis wait times - The i Paper

The female scientists who finally found an answer to endometriosis wait times The i Paper

Published: Oct. 18, 2025, 5 a.m.
Read Full Article
People are applauding Dylan Sprouse for his interview at the Victoria's Secret show - Anabel

People are applauding Dylan Sprouse for his interview at the Victoria's Secret show Anabel

Published: Oct. 17, 2025, 6:17 p.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!